Machine learning for comprehensive forecasting of Alzheimer's Disease progression

Most approaches to machine learning from electronic health data can only predict a single endpoint.The ability to simultaneously simulate dozens of patient characteristics is a crucial step towardspersonalized medicine for Alzheimer's Disease. Here, we use an unsupervised machine learning modelcalled a Conditional Restricted Boltzmann Machine (CRBM) to simulate detailed patient trajectories.We use data comprising 18-month trajectories of 44 clinical variables from 1909 patients with MildCognitive Impairment or Alzheimer's Disease to train a model for personalized forecasting of diseaseprogression. We simulate synthetic patient data including the evolution of each sub-component ofcognitive exams, laboratory tests, and their associations with baseline clinical characteristics. Syntheticpatient data generated by the CRBM accurately refect the means, standard deviations, and correlationsof each variable over time to the extent that synthetic data cannot be distinguished from actual databy a logistic regression. Moreover, our unsupervised model predicts changes in total ADAS-Cog scoreswith the same accuracy as specifcally trained supervised models, additionally capturing the correlationstructure in the components of ADAS-Cog, and identifes sub-components associated with word recallas predictive of progression.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Blog

Digital Twins: A Tool for Risk Mitigation in the Era of COVID-19

Blog

CB Insights 2020 Digital Health 150: Unlearn.AI named in List of Most Innovative Digital Health Startups

Blog

Embracing Innovation to Move Forward

At Unlearn, our goal is to use the data available from historical trials, to generate new evidence to inform and advance research.
Unlearn is thrilled to be recognized as a contributing member of the international community of pioneers in health.
In what ways can we mitigate risk and apply innovative solutions to unstable trials in the wake of COVID-19?